Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

December 31, 2025

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Ipilimumab

Anti-CTLA-4

DRUG

Cemiplimab

PD-1 inhibition

RADIATION

SBRT

Stereotactic Body Radiotherapy

Trial Locations (1)

RECRUITING

Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam

All Listed Sponsors

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER